Medical Management of Malignant Melanoma

Overview

Journal Aust Prescr

Date 2015 Dec 10

PMID 26648623

Citations 16

Authors

Victoria Atkinson

Affiliations

Soon will be listed here.

Abstract

The treatment and outcomes for people with metastatic melanoma have changed considerably in the past few years with the introduction of targeted anticancer drugs. About half of the patients with metastatic melanoma will have activating mutations in the BRAF gene. These people may benefit from a BRAF inhibitor (vemurafenib or dabrafenib) or a MEK inhibitor (trametinib). Addition of a MEK inhibitor to a BRAF inhibitor improves progression-free survival and alters the adverse effect profile. Ipilimumab is another drug indicated for metastatic melanoma. It works by altering the patient's own immune response to the tumour. Toxicities are common with these drugs and include arthralgias, fatigue, photosensitivity, squamous cell carcinomas, fever, diarrhoea, pruritus and immune-related adverse effects.

Citing Articles

A Narrative Review of Current Knowledge on Cutaneous Melanoma.

Caraban B, Aschie M, Deacu M, Cozaru G, Pundiche M, Orasanu C Clin Pract. 2024; 14(1):214-241.

PMID: 38391404 PMC: 10888040. DOI: 10.3390/clinpract14010018.

HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?.

Seo M, Straume O, Akslen L, Cairns J Pharmacoecon Open. 2020; 4(3):529-539.

PMID: 31989465 PMC: 7426343. DOI: 10.1007/s41669-019-00193-8.

Binimetinib plus encorafenib for metastatic melanoma.

Aust Prescr. 2019; 42(5):168.

PMID: 31631932 PMC: 6787304. DOI: 10.18773/austprescr.2019.057.

In vitro selective cytotoxicity of the dietary chalcone cardamonin (CD) on melanoma compared to healthy cells is mediated by apoptosis.

Berning L, Scharf L, Aplak E, Stucki D, von Montfort C, Reichert A PLoS One. 2019; 14(9):e0222267.

PMID: 31553748 PMC: 6760786. DOI: 10.1371/journal.pone.0222267.

Synthetically modified methoxsalen for enhanced cytotoxicity in light and dark reactions.

Guillon C, Jan Y, Foster N, Ressner J, Heck D, Laskin J Bioorg Med Chem Lett. 2019; 29(4):619-622.

PMID: 30638875 PMC: 6364570. DOI: 10.1016/j.bmcl.2018.12.048.

References

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D . Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2014; 372(1):30-9. DOI: 10.1056/NEJMoa1412690. View

ODay S, Hamid O, Urba W . Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007; 110(12):2614-27. DOI: 10.1002/cncr.23086. View

Sosman J, Kim K, Schuchter L, Gonzalez R, Pavlick A, Weber J . Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366(8):707-14. PMC: 3724515. DOI: 10.1056/NEJMoa1112302. View

Flaherty K, Robert C, Hersey P, Nathan P, Garbe C, Milhem M . Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367(2):107-14. DOI: 10.1056/NEJMoa1203421. View

Menzies A, Haydu L, Visintin L, Carlino M, Howle J, Thompson J . Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res. 2012; 18(12):3242-9. DOI: 10.1158/1078-0432.CCR-12-0052. View

Long G, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J . Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014; 371(20):1877-88. DOI: 10.1056/NEJMoa1406037. View

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

Brose M, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R . BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002; 62(23):6997-7000. View

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

10.

Robert C, Long G, Brady B, Dutriaux C, Maio M, Mortier L . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014; 372(4):320-30. DOI: 10.1056/NEJMoa1412082. View

11.

Robert C, Thomas L, Bondarenko I, ODay S, Weber J, Garbe C . Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364(26):2517-26. DOI: 10.1056/NEJMoa1104621. View

12.

Topalian S, Sznol M, Mcdermott D, Kluger H, Carvajal R, Sharfman W . Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014; 32(10):1020-30. PMC: 4811023. DOI: 10.1200/JCO.2013.53.0105. View

13.

Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J . Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16. PMC: 3549296. DOI: 10.1056/NEJMoa1103782. View

14.

Hauschild A, Grob J, Demidov L, Jouary T, Gutzmer R, Millward M . Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380(9839):358-65. DOI: 10.1016/S0140-6736(12)60868-X. View

15.

Larkin J, Ascierto P, Dreno B, Atkinson V, Liszkay G, Maio M . Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371(20):1867-76. DOI: 10.1056/NEJMoa1408868. View

16.

Ascierto P, Minor D, Ribas A, Lebbe C, OHagan A, Arya N . Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013; 31(26):3205-11. DOI: 10.1200/JCO.2013.49.8691. View

17.

Flaherty K, Infante J, Daud A, Gonzalez R, Kefford R, Sosman J . Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367(18):1694-703. PMC: 3549295. DOI: 10.1056/NEJMoa1210093. View